<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541034</url>
  </required_header>
  <id_info>
    <org_study_id>05-051</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-05051</secondary_id>
    <nct_id>NCT00541034</nct_id>
  </id_info>
  <brief_title>Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Phase II Study of Pentostatin With Cyclophosphamide and Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Pentostatin may stop the growth of cancer cells by blocking some of the enzymes
      needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, work in
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping
      them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in
      different ways. Some block the ability of cancer cells to grow and spread. Others find cancer
      cells and help kill them or carry cancer-killing substances to them. Giving pentostatin
      together with cyclophosphamide and rituximab may kill more cancer cells.

      PURPOSE: This phase II trial is studying the side effects and how well giving pentostatin
      together with cyclophosphamide and rituximab works in treating patients with previously
      untreated chronic lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine the frequency of response in patients with previously untreated,
           intermediate- or high-risk B-cell chronic lymphocytic leukemia (CLL) treated with
           pentostatin, cyclophosphamide, and rituximab.

        -  To characterize the toxicity of this regimen in these patients.

      OUTLINE: Patients receive cyclophosphamide IV followed by pentostatin IV on day 1 in course
      1. Beginning in course 2 and in all subsequent courses, patients receive cyclophosphamide IV
      on day 1, pentostatin IV on day 1, and rituximab IV on day 1 or on days 1 and 2. Treatment
      repeats every 3 weeks for up to 6 courses in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed at least every 3 months for 1
      year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Objective Response</measure>
    <time_frame>2 years</time_frame>
    <description>The major criteria for determination of response to therapy in patients with CLL include physical examination and examination of the peripheral blood and bone marrow. Radiographic studies are not required but those that were abnormal pre-treatment, will be repeated to document the degree of maximal response.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>cyclophosphamide, pentostatin &amp; rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV followed by pentostatin IV on day 1 in course 1. Beginning in course 2 and in all subsequent courses, patients receive cyclophosphamide IV on day 1, pentostatin IV on day 1, and rituximab IV on day 1 or on days 1 and 2. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>cyclophosphamide, pentostatin &amp; rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>cyclophosphamide, pentostatin &amp; rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentostatin</intervention_name>
    <arm_group_label>cyclophosphamide, pentostatin &amp; rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of chronic lymphocytic leukemia (CLL), as evidenced by an absolute
             lymphocytosis in the blood of at least 5,000 lymphocytes per microliter OR bone marrow
             lymphocytosis ≥ 30% of all nucleated cells

               -  Previously untreated disease

          -  Meets 1 of the following risk criteria as defined by the three-stage Rai system

               -  Intermediate-risk disease

                    -  Must meet the criteria for active disease as defined by the NCI Working
                       Group guidelines including the following:

                         -  Weight loss

                         -  Fatigue

                         -  Fevers

                         -  Evidence of progressive marrow failure

                         -  Splenomegaly

                         -  Progressive lymphadenopathy

                         -  Progressive lymphocytosis with a rapid doubling time

               -  High-risk disease

          -  Malignant lymphocytes must demonstrate B-cells via immunophenotypic or
             immunohistochemical analysis

          -  Patients with small lymphocytic lymphoma (CLL type) are eligible

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  Karnofsky performance status 60-100%

          -  Total bilirubin ≤ 2.0 mg/dL (patients with Gilbert disease or autoimmune hemolytic
             anemia should have an evaluation for other causes of hyperbilirubinemia, but if none
             are found they may be enrolled regardless of serum bilirubin)

          -  Total creatinine ≤ 2.0 mg/dL OR creatinine clearance &gt; 50 mL/min

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Patients with autoimmune hemolytic anemia or autoimmune thrombocytopenia are eligible
             for treatment on this protocol regardless of disease stage

        Exclusion criteria:

          -  Significant active infections

          -  Ongoing hepatitis B infection, specifically hepatitis B antigen or surface antigen
             positivity

               -  Patients who are hepatitis B antibody positive are eligible for this protocol

        PRIOR CONCURRENT THERAPY:

          -  Concurrent prednisone allowed provided it is used as brief courses (≤ 7 days) for
             inflammatory conditions unrelated to CLL

          -  No prior cytotoxic therapy or rituximab for this cancer

          -  No concurrent radiotherapy or other chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Lamanna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renier Brentjens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <results_first_submitted>January 9, 2017</results_first_submitted>
  <results_first_submitted_qc>January 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2017</results_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage II small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Patients</title>
          <description>All patients who received cyclophosphamide, pentostatin and rituximab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>All patients who received cyclophosphamide, pentostatin and rituximab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Objective Response</title>
        <description>The major criteria for determination of response to therapy in patients with CLL include physical examination and examination of the peripheral blood and bone marrow. Radiographic studies are not required but those that were abnormal pre-treatment, will be repeated to document the degree of maximal response.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients who received cyclophosphamide, pentostatin and rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Objective Response</title>
          <description>The major criteria for determination of response to therapy in patients with CLL include physical examination and examination of the peripheral blood and bone marrow. Radiographic studies are not required but those that were abnormal pre-treatment, will be repeated to document the degree of maximal response.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Nodular Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease (SD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression of Disease (POD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>All patients who received cyclophosphamide, pentostatin and rituximab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pharyngeal mucositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Glucose, high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Phosphate, low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Potassium, high (hyperkalemia)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sodium, low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Renier Brentjens</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>1212-639-7053</phone>
      <email>brentjer@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

